Payment overview · 2025
General Payments
$262.25
13 reported records · 10 companies
Healthcare provider profile · identity verified
Danielle Sorano, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · NORWICH, CT · NPI 1144995424
Verified facts
What the public records show
CMS Open Payments records show Danielle Sorano, APRN received $262.25 in general payments during 2025 across 13 reported records.
Gilead Sciences, Inc. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Qulipta, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $57.84 | 22.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.52 | 13.9% | 2 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $24.52 | 9.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.74 | 9.1% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.67 | 8.6% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.77 | 8.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.21 | 7.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.00 | 7.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.79 | 7.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.19 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $262.25 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
68 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 378 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 330 | 76 |
| Lisinopril | Lisinopril | 324 | 68 |
| Metformin Hcl | Metformin Hcl | 270 | 61 |
| Gabapentin | Gabapentin | 254 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 246 | 54 |
| Omeprazole | Omeprazole | 235 | 50 |
| Losartan Potassium | Losartan Potassium | 224 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 203 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 28 |
| Trazodone Hcl | Trazodone Hcl | 151 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 138 | 21 |
| Furosemide | Furosemide | 129 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 18 |
| Ozempic | Semaglutide | 94 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 19 |
| Ibuprofen | Ibuprofen | 89 | 34 |
| Potassium Chloride | Potassium Chloride | 88 | 18 |
| Simvastatin | Simvastatin | 81 | 21 |
| Famotidine | Famotidine | 79 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 75 | 14 |
| Jardiance | Empagliflozin | 73 | 20 |
| Alendronate Sodium | Alendronate Sodium | 70 | 13 |
| Montelukast Sodium | Montelukast Sodium | 69 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 68 | 45 |
| Januvia | Sitagliptin Phosphate | 67 | 17 |
| Pregabalin | Pregabalin | 65 | 18 |
| Eliquis | Apixaban | 64 | suppressed |
| Meloxicam | Meloxicam | 63 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 62 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 15 |
| Carvedilol | Carvedilol | 60 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 59 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 28 |
| Glipizide Er | Glipizide | 56 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 20 |
| Glipizide | Glipizide | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 14 |
| Methocarbamol | Methocarbamol | 48 | 11 |
| Mirtazapine | Mirtazapine | 46 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | suppressed |
| Atenolol | Atenolol | 43 | suppressed |
| Baclofen | Baclofen | 43 | 11 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | suppressed |
| Spironolactone | Spironolactone | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Lorazepam | Lorazepam | 36 | 12 |
| Finasteride | Finasteride | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Nystatin | Nystatin | 29 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 12 |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 13 |
| Ezetimibe | Ezetimibe | 24 | 11 |
| Lidocaine | Lidocaine | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 16 |
| Xtampza Er | Oxycodone Myristate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Nabumetone | Nabumetone | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Primidone | Primidone | 19 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 12 |
| Prednisone | Prednisone | 18 | suppressed |
| Loperamide | Loperamide Hcl | 17 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $262.25 · 13 records | Gilead Sciences, Inc. | BRIXADI, CAPVAXIVE, Cologuard Collection Kit, ENFLONSIA, NURTEC ODT, Omnipod, QULIPTA, Qelbree, REXULTI, ROTATEQ, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Qulipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error